Browsing by Author "Burgui, Cristina"
Now showing 1 - 4 of 4
Results Per Page
Sort Options
- Enhanced surveillance of COVID-19 in secondary care in Europe: a tale of two wavesPublication . Mokogwu, Damilola; Hamilton, Mark; Harvey, Ciaran; Elgohari, Suzanne; Burgui, Cristina; Mazagatos, Clara; Galtier, Florence; Seyler, Lucie; Machado, Ausenda; Jonikaite, Indre; Lazar, Mihaela; Rath, Barbara; Mutch, Heather; McMahon, James; Ladbury, Georgia; Akinnawo, Ayodele; Martínez-Baz, Iván; Larrauri, Amparo; Laine, Fabrice; Fico, Albana; Demuyser, Thomas; Kislaya, Irina; Gefenaite, Giedre; Cherciu, Carmen; Harrabi, Myriam; MC Rose, Angela; I-MOVE study groupBackground: The I-MOVE-COVID-19 Consortium was established to conduct surveillance of hospitalised COVID-19 cases in nine European countries, aiming to describe the clinical and epidemiological characteristics of severe COVID-19 in order to inform public health response. Methods: Data are pooled from 11 participating sites; two (England and Scotland) submitting national data, with the remainder being from a selection of hospitals. Descriptive analysis is performed on the pooled dataset overall and comparing data on patients admitted from week 5 to 28 of 2020 (“first wave”) vs those admitted later (“second wave”). Results: Data on 84,297 hospitalised patients were submitted for 01 February 2020 - 31 January 2021. Fifty-six percent of cases (46,907/84,193) were male and median age was 69 years. Where information was available, 44% (25,344 /57,769) patients were recorded as having at least one chronic condition. Ninety-five percent (7,868/8,270 and 90% (5,606/6,231) were reported with respiratory and febrile presentations respectively. Twenty-four percent (18,795/78,955) were admitted to intensive care units (ICU) and 26% (19,805/76,764) died in hospital (all sites); 12% (3,305/28,262) and 20% (5,454/27,066) respectively for all sites except England (where ICU reporting is mandated, biasing the dataset towards more severe outcomes as this site represents >50% of all cases). As a percentage of all hospital admissions, both ICU admissions and deaths decreased significantly between the first and second waves in both sexes and across all age- groups, apart from the over 75s. Conclusions: Results from this multicentre European surveillance system suggest that about one in 10 hospitalised COVID-19 patients are admitted to ICU and one in five have fatal outcomes. Fatality and ICU admission were lower in the second wave compared with the first.
- Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021Publication . Rose, Angela M.C.; Nicolay, Nathalie; Sandonis Martín, Virginia; Mazagatos, Clara; Petrović, Goranka; Niessen, F Annabel; Machado, Ausenda; Launay, Odile; Denayer, Sarah; Seyler, Lucie; Baruch, Joaquin; Burgui, Cristina; Loghin, Isabela I.; Domegan, Lisa; Vaikutytė, Roberta; Husa, Petr; Panagiotakopoulos, George; Aouali, Nassera; Dürrwald, Ralf; Howard, Jennifer; Pozo, Francisco; Sastre-Palou, Bartolomé; Nonković, Diana; Knol, Mirjam J.; Kislaya, Irina; Luong Nguyen, Liem binh; Bossuyt, Nathalie; Demuyser, Thomas; Džiugytė, Aušra; Martínez-Baz, Iván; Popescu, Corneliu; Duffy, Róisín; Kuliešė, Monika; Součková, Lenka; Michelaki, Stella; Simon, Marc; Reiche, Janine; Otero-Barrós, María Teresa; Lovrić Makarić, Zvjezdana; Bruijning-Verhagen, Patricia C.J.L.; Gómez, Verónica; Lesieur, Zineb; Barbezange, Cyril; Van Nedervelde, Els; Borg, Maria-Louise; Castilla, Jesús; Lazar, Mihaela; O’Donnell, Joan; Jonikaitė, Indrė; Demlová, Regina; Amerali, Marina; Wirtz, Gil; Tolksdorf, Kristin; Valenciano, Marta; Bacci, Sabrina; Kissling, Esther; I-MOVE-COVID-19 Hospital Study Team; VEBIS Hospital Study TeamIntroduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90–179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.
- Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022Publication . Rose, Angela M.C.; Nicolay, Nathalie; Sandonis Martín, Virginia; Mazagatos, Clara; Petrović, Goranka; Baruch, Joaquin; Denayer, Sarah; Seyler, Lucie; Domegan, Lisa; Launay, Odile; Machado, Ausenda; Burgui, Cristina; Vaikutyte, Roberta; Niessen, F Annabel; Loghin, Isabela I.; Husa, Petr; Aouali, Nassera; Panagiotakopoulos, George; Tolksdorf, Kristin; Horváth, Judit Krisztina; Howard, Jennifer; Pozo, Francisco; Gallardo, Virtudes; Nonković, Diana; Džiugytė, Aušra; Bossuyt, Nathalie; Demuyser, Thomas; Duffy, Róisín; Luong Nguyen, Liem binh; Kislaya, Irina; Martínez-Baz, Iván; Gefenaite, Giedre; Knol, Mirjam J.; Popescu, Corneliu; Součková, Lenka; Simon, Marc; Michelaki, Stella; Reiche, Janine; Ferenczi, Annamária; Delgado-Sanz, Concepción; Lovrić Makarić, Zvjezdana; Cauchi, John Paul; Barbezange, Cyril; Van Nedervelde, Els; O’Donnell, Joan; Durier, Christine; Guiomar, Raquel; Castilla, Jesús; Jonikaite, Indrė; Bruijning-Verhagen, Patricia C.J.L.; Lazar, Mihaela; Demlová, Regina; Wirtz, Gil; Amerali, Marina; Dürrwald, Ralf; Kunstár, Mihály Pál; Kissling, Esther; Bacci, Sabrina; Valenciano, Marta; I-MOVE-COVID-19 hospital study team; VEBIS hospital study team; Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to authors above)Introduction: The I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). Methods: In both networks, 46 hospitals (13 countries) follow a similar test-negative case-control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received < 150 and ≥ 150 days after last PSV dose). We measured VE overall, by vaccine category/product, age group and time since first mRNA booster dose, adjusting by site as a fixed effect, and by swab date, age, sex, and presence/absence of at least one commonly collected chronic condition. Results: We included 2,779 cases and 2,362 controls. The VE of all vaccine products combined against hospitalisation for laboratory-confirmed SARS-CoV-2 was 43% (95% CI: 29-54) for complete PSV (with last dose received ≥ 150 days before onset), while it was 59% (95% CI: 51-66) after addition of one booster dose. The VE was 85% (95% CI: 78-89), 70% (95% CI: 61-77) and 36% (95% CI: 17-51) for those with onset 14-59 days, 60-119 days and 120-179 days after booster vaccination, respectively. Conclusions: Our results suggest that, during the Omicron period, observed VE against SARI hospitalisation improved with first mRNA booster dose, particularly for those having symptom onset < 120 days after first booster dose.
- Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021Publication . Kissling, Esther; Hooiveld, Mariette; Sandonis Martín, Virginia; Martínez-Baz, Iván; William, Naoma; Vilcu, Ana-Maria; Mazagatos, Clara; Domegan, Lisa; de Lusignan, Simon; Meijer, Adam; Machado, Ausenda; Brytting, Mia; Casado, Itziar; Murray, Josephine-L.K.; Belhillil, Sylvie; Larrauri, Amparo; O’Donnell, Joan; Tsang, Ruby; de Lange, Marit; Rodrigues, Ana Paula; Riess, Maximilian; Castilla, Jesús; Hamilton, Mark; Falchi, Alessandra; Pozo, Francisco; Dunford, Linda; Cogdale, Jade; Jansen, Tessa; Guiomar, Raquel; Enkirch, Theresa; Burgui, Cristina; Sigerson, Debbie; Blanchon, Thierry; Martínez Ochoa, Eva María; Connell, Jeff; Ellis, Joanna; van Gageldonk-Lafeber, Rianne; Kislaya, Irina; Rose, Angela M.C.; Gomez, Verónica; Nunes, Baltazar; Roquette, Rita; Silva, Adriana; Melo, Aryse; Costa, Inês; Verdasca, Nuno; Conde, Patrícia; Valenciano, Marta; I-MOVE-COVID-19 primary care study teamThe I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination.